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Abstract
Background: Premature menopause is a major concern of younger women undergoing adjuvant
therapy for breast cancer. Hormone replacement therapy is contraindicated in women with a
history of breast cancer. Non-hormonal medications show a range of bothersome side-effects.
There is growing evidence that cognitive behavioral therapy (CBT) and physical exercise can have
a positive impact on symptoms in naturally occurring menopause. The objective of this study is to
investigate the efficacy of these interventions among women with breast cancer experiencing
treatment-induced menopause.
Methods/design:  In a randomized, controlled, multicenter trial, we are evaluating the
effectiveness of CBT/relaxation, of physical exercise and of these two program elements combined,
in reducing menopausal symptoms, improving sexual functioning, reducing emotional distress, and
in improving the health-related quality of life of younger breast cancer patients who experience
treatment-induced menopause. 325 breast cancer patients (aged < 50) are being recruited from
hospitals in the Amsterdam region, and randomly allocated to one of the three treatment groups
or a 'waiting list' control group. Self-administered questionnaires are completed by the patients at
baseline, and at 12 weeks (T1) and 6 months (T2) post-study entry. Upon completion of the study,
women assigned to the control group will be given the choice of undergoing either the CBT or
physical exercise program.
Discussion: Cognitive behavioral therapy and physical exercise are potentially useful treatments
among women with breast cancer undergoing treatment-induced, premature menopause. For
these patients, hormonal and non-hormonal therapies are contraindicated or have a range of
bothersome side-effects. Hence, research into these interventions is needed, before dissemination
and implementation in the current health care system can take place.
Trial registration: The study is registered at the Netherlands Trial Register (NTR1165) and
ClinicalTrials.gov (NCT00582244).
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Background
Breast cancer is the most common cancer among women
in the Netherlands, with an incidence of 71 per 100.000
person years, and a lifetime risk of 10%. [1] Nearly 25%
of all women with breast cancer are premenopausal at the
time of diagnosis. [2] Ovarian damage is the most signifi-
cant long-term sequela of chemotherapy and/or endo-
crine treatment in premenopausal women. [3,4] It can
lead to an earlier onset of menopause, with age and dura-
tion of treatment being its strongest predictors. [5] Prema-
ture menopause is a major concern of younger women
undergoing adjuvant therapy for breast cancer [6], as
effective and safe treatment options are not currently
available.
Premature menopause and menopausal symptoms
Primary menopausal symptoms include hot flushes, night
sweats, vaginal dryness, decreased libido, dysuria and uri-
nary incontinence. Secondary symptoms include insom-
nia due to night sweats, dyspareunia because of vaginal
dryness, weight gain, and psychological distress. [3,7,8]
Previous studies have indicated that breast cancer patients
are more likely to experience menopausal symptoms than
age-matched healthy controls, [9,10] and that especially
younger breast cancer patients are affected by vasomotor
and dystrophic symptoms. [7] Menopausal symptoms are
an important source of morbidity [11] and discomfort
[7,8] in patients with breast cancer and they may adversely
affect women's sexual functioning, body image, and over-
all health-related quality of life. [6,9,12,13]
Among menopausal symptoms, hot flushes are consid-
ered to be the most disruptive, with prevalence rates
between 63% and 80% in breast cancer patients. [8,14-
17] Dysfunction of the thermoregulatory center in the
hypothalamus due to (natural or treatment-induced)
changes in estrogen levels has been postulated to be the
cause of hot flushes. [18] As stress, spicy food and alcohol
intake potentially affect the levels of serotonin, they may
also increase the frequency and intensity of hot flushes.
[19,20]
Treatments for menopausal symptoms
Hormonal replacement therapy (HRT) is highly effective
in alleviating vasomotor symptoms associated with men-
opause. [21] However, HRT is contraindicated in women
with a history of breast cancer. [22] Some of the non-hor-
monal medications, e.g. clonidine and selective serotonin
receptor inhibitors, have been shown to be moderately
effective in reducing vasomotor symptoms associated
with menopause. [23] However, they have a range of
bothersome side-effects, such as nausea, dizziness and dry
mouth. [24-27]
There is growing evidence that cognitive behavioral ther-
apy and physical exercise can have a positive impact on
symptoms in naturally occurring menopause. [28-30]
Cognitive behavioral therapy (CBT) focuses on the rela-
tionships between thoughts, feelings and behavior, and is
aimed primarily at stress reduction. CBT includes the fol-
lowing components: information about symptoms, mon-
itoring and modifying precipitants, relaxation and stress
management, cognitive restructuring of unhelpful
assumptions and automatic thoughts, and encouraging
helpful behavioral strategies. [28] A four session CBT
including relaxation was found to be as beneficial in the
reduction of vasomotor symptoms as HRT in a study of
women undergoing natural menopause, and more effec-
tive than HRT in improving mood. [31]
Several studies have reported that relaxation therapy can
effectively reduce hot flushes in naturally menopausal
women, which may be explained by the reduction of sym-
pathetic nervous system activity. [29,32,33] Significant
associations have been observed between ratings of stress
and reports of hot flushes, [19,20] suggesting that modifi-
cation of precipitants of hot flushes and stress manage-
ment may decrease the frequency and severity of hot
flushes.
To our knowledge, only two studies have investigated the
efficacy of behavioral interventions for the treatment of
menopausal symptoms among women with breast can-
cer. In a randomized, prospective trial, Ganz et al. [34]
found a significant, positive effect of a treatment package
including counseling, pharmacological and behavioral
interventions on menopausal symptoms and sexual func-
tioning among women with a history of breast cancer. In
a small randomised study (n = 16), relaxation training
yielded a trend toward lower levels of hot flushes and
night sweats, and a significant positive effect on psycho-
logical distress as compared to a control condition. [35]
A number of studies have generated results indicative of a
beneficial effect of physical exercise on hot flushes occur-
ring in naturally menopausal women. Two large popula-
tion-based, cross-sectional studies carried out among
Swedish women [36,37] indicated that regular vigorous
exercise at least 3 hours per week is associated with a sig-
nificantly lower risk of hot flushes. Only 5% of highly
active women experienced severe hot flushes as compared
to 15% of women who had little or no weekly exercise. It
has been hypothesized that the positive effect of exercise
on vasomotor symptoms may be due to elevated levels of
endorphins that regulate central thermoregulation.
[36,37] The findings of these observational investigations
were further supported by two randomized studies con-
ducted in Sweden and Japan [30,38] showing that a phys-
ical exercise program of at least 12 weeks had a significantBMC Women's Health 2009, 9:15 http://www.biomedcentral.com/1472-6874/9/15
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positive effect on climacteric symptoms and health-
related quality of life. However, one randomized study
[39] has reported increased rates of hot flushes among
obese, sedentary, postmenopausal women participating
in an exercise program. This latter finding may be related
to weight loss and decreased fat content leading to a
decline in estrogen levels. [40]
Although cognitive behavioral therapy and physical exer-
cise have been shown to have favorable effects in women
undergoing natural menopause, these interventions have
not yet been investigated in the context of menopausal
symptoms experienced by breast cancer patients undergo-
ing treatment-induced menopause.
Current study
The present study is systematically evaluating the effec-
tiveness of CBT/relaxation, of physical exercise and of
these two program elements combined, in reducing men-
opausal symptoms, improving sexual functioning, reduc-
ing emotional distress, and in improving the health-
related quality of life of younger breast cancer patients
who experience treatment-induced menopause. In a rand-
omized, controlled, multicenter trial, we are comparing
CBT (A), physical exercise (B) and the combination of
both interventions (AB) to a 'waiting list' control group.
We hypothesize that women in the CBT group, the physi-
cal exercise group or the combined group will report sig-
nificantly greater reduction in overall levels of
menopausal symptoms than patients in the usual care,
waiting list control group. Furthermore, we hypothesize
that women participating in the combined intervention
will report significantly greater reduction in overall levels
of menopausal symptoms than those participating in the
CBT only or in the exercise only groups. Due to different
mechanisms of action, we expect that the combined
modalities will be more effective than either modality
alone. CBT is expected to lead to significant reductions in
menopausal symptoms via cognitive restructuring and
stress management, while physical exercise is expected to
impact primarily on metabolism of neurotransmitters
responsible for thermoregulation. Finally, we hypothesize
that women exposed to the interventions (groups A, B and
AB) will report significantly more improvement in sexual
functioning, body- and self-image, psychological distress,
and generic health-related quality of life than those in the
control group.
If demonstrated to be effective, the availability of such a
structured supportive intervention program will be a wel-
come addition to standard medical treatment offered to
breast cancer patients with treatment-induced meno-
pause. It is anticipated that such a program will have
direct benefit in terms of symptom relief and the improve-
ment of patients' health related quality of life.
Methods and design
Using a 2 × 2 full-factorial design patients are randomly
allocated to one of the four following conditions: CBT,
physical exercise, the combination of both interventions
or a 'waiting list' control group. The design will allow for
testing of the main effect of CBT, the main effect of phys-
ical exercise, and the additive or interactive effects of CBT
and exercise on menopausal symptoms, the primary out-
come measure. Secondary outcomes will include sexual
functioning, urinary symptoms, body image and self-
image, psychological distress and HRQL. The design of
the study and the anticipated flow of the participants are
graphically shown in Figure 1. The institutional review
boards of all participating hospitals have approved the
study. The study is registered at the Netherlands Trial Reg-
ister (NTR1165) and ClinicalTrials.gov (NCT00582244).
Study sample
The study sample will be composed of 325 women,
younger than 50 years of age, with histologically con-
firmed primary breast cancer (stages: T1 – T4, N0 – N1
and M0). All women will have been premenopausal at the
time of diagnosis, have completed adjuvant chemother-
apy a minimum of 4 months and a maximum of 5 years
prior to study entry, and will currently be disease-free.
Hormonal therapy can still be ongoing. Potentially eligi-
ble women are screened for the presence of at least one of
the following 3 menopausal symptoms during the previ-
ous week: hot flushes, sweating and/or vaginal dryness.
Women are excluded from the study if they lack basic pro-
ficiency in Dutch, if they have serious cognitive or psychi-
atric problems, or serious physical comorbidity that
would preclude them from participating in a physical
exercise program. Since physical exercise may be contrain-
dicated as a treatment for hot flushes in obese women,
[39] patients with a BMI ? 30 are excluded from the study.
Patients participating in concurrent studies or rehabilita-
tion programs containing comparable psychosocial inter-
ventions are also excluded.
Sample size
The FACT-ES scale, assessing endocrine symptoms [41] is
the primary outcome on which sample size calculations
are based. Specifically, mean group differences in the
FACT-ES scores at 12 weeks and 6 months follow-up, con-
trolling for baseline value, will serve as the primary end-
point of the study. With a total sample of 260 women (65
per group), and under the assumption of no interaction,
the study will have 90% power to detect an effect size of
0.4 for the main effects of CBT (n = 130) and physical
exercise (n = 130), with the p-value set at 0.05. If the com-
bined effects of CBT and physical exercise are cumulative,BMC Women's Health 2009, 9:15 http://www.biomedcentral.com/1472-6874/9/15
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or if the effect of CBT varies as a function of exposure to
exercise or vice versa, (i.e. there is a significant interaction
between CBT and exercise), this number of patients will
allow testing each of the 4 cells in the factorial design
(group A, B, AB and control group) separately with 80%
power to detect an effect size of 0.5, again with p-value set
at 0.05. [42]
We will recruit 325 women into the study, to allow for an
attrition rate of approximately 20% (i.e. women who dis-
continue participation in the study entirely, including fail-
ure to complete all follow-up questionnaires; those
women who discontinue participation in one of the
groups but complete the follow-up assessments will be
included in the analysis). Thus, 260 women will be avail-
able for the primary intention-to-treat analysis.
Recruitment and randomisation
The patients are recruited from hospitals in the Amster-
dam region. Potentially eligible patients are identified
through hospital registries, for the 5-years retrospective
inclusion, and through treating physicians, for the 2-years
prospective inclusion. They are sent a letter signed by their
physician informing them of the study and, if initially
Study flow diagram Figure 1
Study flow diagram.BMC Women's Health 2009, 9:15 http://www.biomedcentral.com/1472-6874/9/15
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interested, asking them to complete a brief questionnaire
to screen for menopausal symptoms. If they have no fur-
ther interest in the study, they are asked to complete a
postcard indicating reasons for not participating. In case
of no response to the questionnaire or the postcard, a
reminder is sent two weeks after the first mailing.
Those women who meet criteria for study entry based on
their questionnaire responses are contacted by telephone
to provide additional information on the study and to
confirm their eligibility. In addition, they receive an exten-
sive baseline questionnaire and informed consent form by
mail. Computerized randomization takes place after
response to both this baseline assessment and the
informed consent. Block randomisation is used to ensure
that each intervention consists of equally sized groups. In
view of the nature of the interventions, blinding of the
participants and the researchers is not possible.
During the follow-up period, self-administered question-
naires are sent to the patients at 12 weeks (T1) and 6
months (T2) post-study entry. Upon completion of the
study, women assigned to the control group will be given
the choice of undergoing either the CBT or physical exer-
cise program.
Interventions
The CBT and relaxation training consist of 6 weekly group
sessions (with 6–8 participants per group) of approxi-
mately 1.5 hours duration. It also includes homework
assignments (e.g. keeping a daily diary to monitor symp-
toms and their precipitants). The CBT program is based
on the work of Hunter et al. [31] It comprises the follow-
ing elements: (1) information and advice about symp-
toms (e.g. hot flushes, night sweats and sexual
functioning); (2) monitoring and modifying precipitants;
(3) relaxation and stress reduction; (4) cognitive restruc-
turing of unhelpful thoughts, elicited by group discussion;
and (5) encouraging helpful behavioral strategies (e.g.
pacing activities). The primary focus of the CBT is on hot
flushes and night sweats, but other symptoms (e.g. vagi-
nal dryness) and problem areas such as sexuality, body-
and self-image, and mood disturbance are also addressed.
Relaxation is demonstrated and practiced during each ses-
sion and an audio CD is provided for practicing at home.
A 'booster' session is held approximately 6 weeks follow-
ing completion of the initial 6 week program. The CBT is
delivered by a social worker or psychologist and an assist-
ant, usually an undergraduate psychology student.
The physical exercise program includes 4 individual con-
tacts with a physiotherapist (one in-clinic intake of 90
minutes, two 15-minute telephone contacts, and a final
60-minute in-clinic session). Its core is an individually tai-
lored, home-based and self-directed physical exercise pro-
gram of 2.5–3 hours per week. During the first, supervised
intake session, the exercise program is individually tai-
lored, taking into consideration lifestyle, past and current
levels of activity, preferences for types of activities (e.g.
walking, cycling, gym exercises, etc.), and any disabilities.
Each woman is provided with a heart-rate monitor, and is
instructed in its use to achieve a target heart rate (60–80%
Karvonen). In weeks 4 and 8, women have a brief tele-
phone contact with the physiotherapist to discuss their
experiences with the program and to make modifications,
if necessary. Additionally, each week a telephone consul-
tation hour is scheduled during which women can call the
physiotherapist to discuss their exercise program, if
desired. At the end of the program (week 12) women visit
the clinic for a final session, during which advice is given
on how best to maintain the level of physical activity (as
used in the program) following completion of the pro-
gram. At this time the data from the heart monitor are
downloaded onto a computer.
Women assigned to the combined intervention group
(AB) undergo the CBT and physical exercise elements of
the program concurrently. To as great an extent as possi-
ble, the on-site CBT and in-clinic exercise training sessions
are scheduled on the same day.
Study measures
The patients' age, education, marital status, work status,
weight and height, medication use (including alternative
medications or therapies for menopausal complaints or
depression) and life style variables (e.g. smoking, physical
activity/exercise) are obtained via questionnaire. Clinical
information, including date of diagnosis and tumor char-
acteristics, and treatment history (type of surgery, possible
breast reconstruction, radiotherapy, chemotherapy, endo-
crine treatments) are abstracted from the patients' medical
records, if possible.
Overall levels of menopausal symptoms
The FACT-ES, an 18-item endocrine symptom scale, is
used to assess overall levels of menopausal symptoms.
[41] It includes both typical (vasomotor symptoms, vagi-
nal dryness) and a-typical symptoms (e.g. weight gain,
headaches) of menopause. The FACT-ES has been used
among breast cancer patients treated by tamoxifen, [41]
and in a sample of Dutch women at increased risk of
breast/ovarian cancer who had undergone prophylactic
oophorectomy. [43] The scale has shown high levels of
reliability (Cronbach's alphas > 0.80 in both studies).
Vasomotor symptoms
Hot flushes and night sweats are assessed by the Hot Flush
Rating Scale. [44] This 7-item questionnaire assesses the
history of hot flushes, their current frequency, severity and
duration (in the past week), emotional reactions, per-BMC Women's Health 2009, 9:15 http://www.biomedcentral.com/1472-6874/9/15
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ceived disruptiveness, and perceived ability to cope with
and control the symptoms. The scale has proven to have
good test-retest reliability across a 2–3 week period (r =
0.80). The measure has been used among breast cancer
patients treated with tamoxifen. [17]
Urinary symptoms
The Bristol Female Lower Urinary Tract Symptoms Ques-
tionnaire (BFLUTS) [45] assesses a wide range of urinary
symptoms and their impact on sexual function and qual-
ity of life. It consists of 5 scales (34 items) assessing incon-
tinence, voiding, filling, sexual function in relation to
urinary problems and the impact on health related quality
of life. For the purpose of the current study, only the 5-
item incontinence scale will be used, including questions
on urge, frequency, stress, unpredictable and nocturnal
incontinence. The scale has shown to have good reliability
(Cronbach's alpha = 0.75).
Sexuality
The Sexual Activity Questionnaire (SAQ) [46] is used to
assess levels of sexual functioning. This 10-item measure
consists of 3 scales: pleasure (desire, enjoyment, satisfac-
tion and current frequency of activities); discomfort (vag-
inal dryness, pain and discomfort during penetration);
and habit (frequency of sexual activity as compared to the
usual level). The SAQ has been used in the British
Tamoxifen Prevention Trial, [47] several studies of
women with breast cancer, [48,49] and of women at
increased risk of developing breast/ovarian cancer who
had undergone prophylactic oophorectomy. [43] The
SAQ has shown to have good reliability (Cronbach's
alphas > 0.70).
Body image and self-image
Body image is assessed by the 4-item scale of the EORTC
breast cancer-specific quality of life questionnaire, the
QLQ-BR23. [50] This scale has been shown to have good
reliability (Cronbach's alpha > 0.70) when employed in
Dutch research settings. We have added two items to
assess self-image, i.e. 'Have you been feeling older as a
result of your treatment for breast cancer' and 'Did your
self-image change as a result of your treatment for breast
cancer?'
Psychological distress
Psychological distress is assessed with the 14-item Hospi-
tal Anxiety and Depression Scale (HADS). [51] The HADS
assesses symptoms of mood disturbance, yielding sepa-
rate scale scores for anxiety and depression, as well as a
total score. Numerous studies have applied the HADS to
assess distress among breast cancer patients. [52,53] The
questionnaire has been validated for use in the Dutch
population, [54] showing good psychometric properties
(Cronbach's alphas of both the anxiety and depression
scales > 0.79).
Generic health-related quality of life
The MOS SF-36 Item Health Survey (SF-36) [55] is used to
assess generic health related quality of life. This 36-item
questionnaire is organized into 8 multi-item scales assess-
ing physical functioning, role functioning-physical, role
functioning-emotional, pain, vitality, social functioning,
mental health, and general health perceptions. Summary
component scores for physical and mental health can also
be calculated. It has been translated, validated and
normed in a large number of languages, including Dutch.
[56] It has also been used in previous studies of younger
patients with breast cancer. [14] We have added one item
to assess quality of sleep in the past month.
Compliance
Records are kept of the number of CBT sessions attended.
Women are also asked to indicate the frequency and dura-
tion of relaxation sessions and other homework assign-
ments. Records are also kept of attendance at the in-
hospital exercise program sessions, and compliance with
the home-based training is determined on the basis of
both self-report and the data registered by the heart rate
monitors. The monitors register frequency and duration
of exercise, total exercise time in and outside the target
zone, average heart rate of total exercise, and calorie
expenditure.
Women who do not complete the entire program are
asked to indicate the reason(s) for their discontinuation
(e.g. illness, lack of motivation, burden, etc.). Every effort
is made to obtain a final, post-intervention assessment for
patients who discontinue the program. This facilitates a
maximum sample size for the primary, intention-to-treat
analysis. Additionally, all women, including those in the
control group, are asked if, during the period of the study,
they had pursued any (other) activities relating to their
menopausal symptoms (e.g. alternative remedies).
Patients' evaluation of the intervention program
At the 12 week evaluation point, women in the 3 interven-
tion arms of the study are asked to complete a brief series
of questions about the perceived efficacy of and satisfac-
tion with the intervention program, whether they would
suggest any changes to the program, and if they would rec-
ommend it to other women experiencing symptoms of
premature menopause.
Statistical analyses
Analysis will first be performed to evaluate the compara-
bility of the intervention and control groups at baseline in
terms of sociodemographic and clinical characteristics.
Student's t-test or appropriate non-parametric statisticsBMC Women's Health 2009, 9:15 http://www.biomedcentral.com/1472-6874/9/15
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will be used, depending on the level of measurement. If,
despite the stratified randomization procedures, the
groups are found not to be comparable on one or more
background variables, those variables will be employed
routinely as covariates in subsequent analyses.
Scores for the FACT-ES, the Hot Flush Rating Scale, the
BFLUTS, the SAQ, the QLQ-BR23 body image scale, the
HADS, and the SF-36 will be calculated according to pub-
lished scoring algorithms. Between-group differences over
time in mean scores will be tested using a two factor
(group × time) multivariate analysis of variance with
repeated measures on the time factor. Effect sizes will be
calculated using standard statistical procedures. All analy-
sis will, to as great an extent as possible, be conducted on
an intention-to-treat basis. In addition, we will perform
per-protocol analyses based on patients who complete the
entire intervention. As indicated previously, the FACT-ES
and the Hot Flush Rating Scale will be used as the primary
study endpoints, and the remaining measures will be con-
sidered as secondary endpoints. For the analysis of these
latter variables, appropriate statistical (p-value) adjust-
ments will be made for multiple testing.
Supplementary analyses will be carried out in which data
relating to compliance with the program elements is taken
into account. Specifically, we will determine whether the
level of compliance (based on attendance records, self-
report data and, in the case of physical exercise, data
stored in the heart rate monitor) is associated significantly
with the changes over time in symptom relief, sexuality,
body image, psychological distress, and health related
quality of life.
Discussion
Menopausal symptoms are common, and may be particu-
larly severe in younger women with breast cancer who
undergo treatment-induced menopause. Effective and
safe treatment options for these symptoms in breast can-
cer patients are needed. Although CBT, relaxation and
physical exercise have been found to have a positive effect
on vasomotor symptoms in women undergoing natural
menopause, they have not been investigated among
women with breast cancer undergoing treatment-induced,
premature menopause.
In the current study, we are systematically evaluating the
effectiveness of CBT/relaxation, of physical exercise and of
these two program elements combined, in reducing men-
opausal symptoms, improving sexual functioning, reduc-
ing emotional distress, and in improving the health-
related quality of life of younger breast cancer patients
who experience treatment-induced menopause.
Methodological considerations
Our study has several strengths. First, the chosen research
design – a 2 × 2 factorial design – will allow us to test the
main effects of CBT and of physical exercise, and the addi-
tive or interactive effects of CBT and exercise. We believe
that this is a robust and efficient design for testing these
broad program elements. Second, the cognitive behavio-
ral therapy under investigation was developed, and its
effectiveness among natural menopausal women was
evaluated by Hunter and colleagues. [31] Cognitive
behavioral therapy resulted in significant reductions in
hot flush frequencies by 59% (baseline vs. follow-up).
Additionally, CBT also reduced anxiety and hot flush
problem ratings. This study lends preliminary support to
CBT as a potentially effective management approach for
the reduction of hot flushes.
Several limitations of the study should be noted. First, a
follow-up of 3 months is relatively short for an interven-
tion study. However, it is similar to that used in previous
studies on the effect of these interventions in women
experiencing a natural menopause. Furthermore, all the
outcomes at follow-up (with the exception of the data
from the heart rate monitor) will be measured by self-
report. Physiological assessment of hot flushes would pro-
vide more objective data, but is not feasible within the
context of this multicenter study.
Conclusion
Cognitive behavioral therapy and physical exercise are
promising treatments among women with breast cancer
undergoing treatment-induced, premature menopause.
For these patients, hormonal and non-hormonal thera-
pies are contraindicated or have a range of bothersome
side-effects. Hence, research into these interventions is
needed, before dissemination and implementation in the
current health care system can take place. The current
study will contribute to the knowledge on the effective-
ness of cognitive behavioral therapy and physical exercise
in younger breast cancer patients.
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